ASCO
Pharma

Akeso's 34% overall survival win comes with caveats

While ivonescimab and chemo's 34% improvement on overall survival exceeded expectations, detailed data from Harmoni-6 are being picked apart.
Angus Liu May 31, 2026 8:00am
Xocova COVID-19

Shionogi's Japan-approved antiviral nets US COVID nod

Jun 1, 2026 11:11am
showdown clash versus vs crash lightning fight dispute

The Oral GLP-1 Tracker: Jefferies reaffirms Foundayo forecast

Jun 1, 2026 9:23am
AstraZeneca booth at AACR 2026

AZ's Imfinzi, Imjudo combo polishes case in early liver cancer

Jun 1, 2026 8:24am
Merck

Will Merck close a gap in sac-TMT's massive ph. 3 program?

Jun 1, 2026 4:30am
lung cancer

ASCO: Lilly tees up expansion into Retevmo’s 'final chapter’

May 31, 2026 8:00am
More News
Fierce Biotech

ASCO: RevMed confident in RAS leadership as rivals square up

May 31, 2026 8:00am

ASCO: J&J positions Erleada to shake up prostate cancer care

May 31, 2026 8:00am

ASCO: Pfizer one-ups J&J in prostate cancer

May 30, 2026 8:00am

ASCO: Incyte positions Monjuvi combo for first-line DLBCL

May 30, 2026 8:00am